Cantor Fitzgerald Reaffirms Overweight Rating for SI-BONE (NASDAQ:SIBN)

Cantor Fitzgerald reiterated their overweight rating on shares of SI-BONE (NASDAQ:SIBN) in a research note published on Tuesday morning,Benzinga reports. Cantor Fitzgerald currently has a $25.00 price objective on the stock. Cantor Fitzgerald also issued estimates for SI-BONE’s FY2025 earnings at ($0.64) EPS.

Several other equities analysts have also commented on the stock. Truist Financial increased their price target on shares of SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Needham & Company LLC increased their target price on shares of SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Tuesday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, SI-BONE currently has a consensus rating of “Buy” and an average price target of $24.50.

SI-BONE Stock Performance

Shares of SI-BONE stock opened at $17.81 on Tuesday. The business has a 50-day simple moving average of $16.01 and a 200-day simple moving average of $14.76. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. SI-BONE has a one year low of $11.70 and a one year high of $19.16. The company has a market cap of $746.92 million, a PE ratio of -19.36 and a beta of 1.17.

SI-BONE (NASDAQ:SIBN) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. The company had revenue of $49.00 million for the quarter, compared to analysts’ expectations of $48.87 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. On average, equities research analysts forecast that SI-BONE will post -0.78 EPS for the current fiscal year.

Insider Activity

In other news, CFO Anshul Maheshwari sold 5,304 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total value of $73,778.64. Following the completion of the sale, the chief financial officer now owns 189,319 shares in the company, valued at approximately $2,633,427.29. This trade represents a 2.73 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Anthony J. Recupero sold 3,670 shares of SI-BONE stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total value of $51,013.00. Following the completion of the sale, the insider now directly owns 222,814 shares in the company, valued at $3,097,114.60. This represents a 1.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 9,311 shares of company stock valued at $130,356 in the last ninety days. 3.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of SI-BONE by 4.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,373 shares of the company’s stock worth $328,000 after buying an additional 988 shares during the last quarter. FMR LLC raised its holdings in shares of SI-BONE by 103.6% in the third quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after acquiring an additional 1,198 shares during the last quarter. Invesco Ltd. lifted its position in shares of SI-BONE by 8.9% in the fourth quarter. Invesco Ltd. now owns 17,203 shares of the company’s stock valued at $241,000 after acquiring an additional 1,413 shares in the last quarter. Rhumbline Advisers lifted its position in shares of SI-BONE by 3.0% in the fourth quarter. Rhumbline Advisers now owns 57,621 shares of the company’s stock valued at $808,000 after acquiring an additional 1,683 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of SI-BONE by 9.4% during the third quarter. Franklin Resources Inc. now owns 20,220 shares of the company’s stock valued at $265,000 after acquiring an additional 1,745 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.